Effectiveness of neuraminidase inhibitors for preventing staff absenteeism during pandemic influenza

Emerging Infectious Diseases

Volumn 13, Issue 3, 2007, Pages 449-457

  Lee, Vernon J ^a,b   Chen, Mark I ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL CENTRE FOR INFECTIOUS DISEASES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR;

ABSENTEEISM; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; INFECTION PREVENTION; INFLUENZA; OUTCOME ASSESSMENT; PANDEMIC; PROPHYLAXIS; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT DURATION; TREATMENT PLANNING;

EID: 33847361565     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1303.060309     Document Type: Article

References (22)

1. World Health Organization. Avian influenza and human pandemic influenza: summary report. Meeting held in Geneva, Switzerland, 7-9 Nov 2005. [cited 2006 Jan 15]. Available from http://www.who.int/mediacentre/events/2005/ avian_influenza/summary_report_Nov_2005_meeting.pdf
2. Lee VJ, Phua KH, Chen MI, Chow A, Ma S, Goh KT, et al. Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore. Emerg Infect Dis. 2006;12:95-102.
3. Balicer RD, Huerta M, Davidovitch N, Grotto I. Cost-benefit of stockpiling drugs for influenza pandemic. Emerg Infect Dis. 2005;11:1280.
4. Cinti S, Chenoweth C, Monto AS. Preparing for pandemic influenza: should hospitals stockpile oseltamivir? Infect Control Hosp Epidemiol. 2005;26:852-4.
5. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet. 2000;355:1845-50.
6. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-72.
7. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235.
8. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-73.
9. Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623-33.
10. Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis. 2002;2:145-55.
11. Cox NJ, Subbarao K. Influenza. Lancet. 1999;354:1277-82.
12. Chow A, Ma S, Ling AE, Chew SK. Influenza-associated deaths in tropical Singapore. Emerg Infect Dis. 2006;12:114-21.
13. Singapore Department of Statistics. Key statistics. [cited 2005 Dec 21]. Available from http://www.singstat.gov.sg/
14. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature. 2004;432:904-6.
15. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A. 2004;101:6146-51.
16. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240-6.
17. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748-54.
18. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-73.
19. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev. 1996;18:64-76.
20. Influenza pandemic planning. Business continuity planning guide. New Zealand Ministry of Economic Development. [cited 2006 Jul 1]. Available from http://www.med.govt.nz/upload/27552/planningguide.pdf
21. Gani R. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis. 2005;11:1355-62.
22. Chik KW, Li CK, Chan PKS, Shing MMK, Lee V, Tam JSL, et al. Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong Med J. 2004;10:103-6.